+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Value-added Medicines Market - Global Forecast 2026-2032- Product Image
Value-added Medicines Market - Global Forecast 2026-2032- Product Image
Sale

Value-added Medicines Market - Global Forecast 2026-2032

  • Report

  • 188 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6277880
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Value-Added Medicines: Executive Summary

Value-added medicines enhance established therapies through improvements such as alternative delivery systems, adherence support, patient-friendly formulations, combination products, packaging, or services. Their strategic role is growing as healthcare systems seek better treatment experiences, more efficient care pathways, and stronger real-world outcomes without relying solely on novel active ingredients. Competitive success depends on demonstrating meaningful clinical, operational, and patient value while meeting regulatory and reimbursement requirements.

How Value-Added Medicines Are Reshaping Pharmaceutical Strategy

The landscape is shifting from product-centric competition toward integrated solutions that address barriers across the treatment journey. Reformulation, device-enabled administration, digital support, specialty distribution, and patient services are increasingly evaluated together rather than as separate features. Regulatory expectations, intellectual-property strategy, evidence generation, and payer engagement are therefore becoming more interconnected. Companies that can document improved adherence, convenience, safety, or healthcare utilization are better positioned to distinguish mature therapies in crowded categories.

Artificial Intelligence’s Cumulative Impact on Value-Added Medicines

Artificial intelligence is influencing value-added medicines across discovery, formulation design, clinical development, manufacturing, and post-market support. It can help identify adherence barriers, segment patient needs, optimize device and packaging concepts, detect quality deviations, and improve demand and supply coordination. AI-enabled patient engagement may also personalize reminders and educational content, although outputs require clinical oversight, privacy safeguards, cybersecurity controls, and validation. The most durable benefit will come from embedding AI into evidence-based workflows rather than treating it as a standalone differentiator.

Regional Insights Across Diverse Healthcare Systems

North America emphasizes differentiated delivery, specialty-care support, patient services, and evidence relevant to payers and providers. Europe places strong weight on health-technology assessment, regulatory consistency, sustainability, and equitable access across national systems. Asia-Pacific combines advanced pharmaceutical capabilities with substantial variation in infrastructure, reimbursement, and digital readiness. Latin America presents opportunities linked to access, convenience, and treatment continuity, while affordability and distribution remain central. The Middle East is increasingly focused on healthcare modernization, local capability, and integrated care. Africa’s priorities often center on dependable supply, simpler administration, community delivery, and solutions suited to uneven healthcare capacity.

Group-Level Priorities: ASEAN, BRICS, EU, G7, GCC, and NATO

ASEAN markets require adaptable solutions that accommodate differing regulatory pathways, income levels, and healthcare infrastructure. BRICS economies combine large and diverse patient populations with growing domestic pharmaceutical capabilities, making local manufacturing, affordability, and access important considerations. The European Union favors harmonized evidence, environmental responsibility, and alignment with national reimbursement processes. G7 systems generally demand robust clinical, economic, and patient-centered evidence alongside high quality standards. GCC countries are prioritizing healthcare transformation, specialized services, and resilient supply chains. NATO members may place additional emphasis on continuity of supply, emergency preparedness, and secure pharmaceutical logistics where healthcare resilience is a strategic concern.

Country Insights: Market Access and Development Priorities

Australia and Canada typically require clear evidence of clinical usefulness, budget relevance, and suitability for geographically dispersed care. Brazil and Mexico benefit from patient-friendly solutions that address access and distribution complexity while navigating distinct public and private channels. China and India combine strong manufacturing and innovation capabilities with varied regional access and affordability needs. France, Germany, Italy, Spain, and the United Kingdom place substantial importance on regulatory compliance, comparative evidence, procurement, and health-system value, though access processes differ by country. Japan often rewards usability, aging-population relevance, and careful adaptation to local clinical practice. South Korea combines advanced digital and pharmaceutical capabilities with demand for differentiated care solutions. Russia presents a more complex operating environment in which supply resilience, localization, and regulatory conditions require close assessment. The United States remains highly influential in specialty medicines, patient-support models, managed-care evidence, and technology-enabled delivery.

Actions for Leaders Building Durable Value

Industry leaders should begin with a clearly defined unmet need and select the value-added feature most likely to improve outcomes, safety, convenience, or care efficiency. Build evidence plans early, linking patient-reported outcomes and adherence with clinical and economic endpoints. Engage regulators, payers, providers, and patient groups before major development decisions, and tailor the value proposition to each healthcare system. Design for manufacturability, supply resilience, accessibility, and environmental performance from the outset. Use AI selectively under strong governance, validate digital tools, protect sensitive data, and maintain human accountability. Finally, manage lifecycle strategy through continuous real-world monitoring and disciplined portfolio prioritization.

Research Methodology for Assessing Value-Added Medicines

This executive summary uses a structured qualitative assessment of value-added medicines across therapeutic design, delivery, patient support, evidence requirements, regulation, reimbursement, manufacturing, and healthcare-system implementation. The analysis compares recurring strategic themes across North America, Latin America, Europe, the Middle East, Africa, and Asia-Pacific, and considers the specified country and multilateral group contexts. Insights are organized around observable industry practices and policy dynamics, with emphasis on differences in infrastructure, access, evidence expectations, and supply-chain resilience. No market estimates, market shares, forecasts, or company-specific claims are used.

Conclusion: Competing Through Demonstrable Patient and System Value

Value-added medicines are becoming an important route for improving established therapies and addressing practical barriers to treatment. Their potential depends less on incremental novelty than on credible evidence that a formulation, device, service, or digital component produces meaningful benefits for patients and healthcare systems. Leaders that combine human-centered design, rigorous evidence, regional adaptation, responsible technology, and resilient operations can create stronger and more sustainable value across diverse healthcare environments.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Value-added Medicines Market, by Therapeutic Area
7.1. Introduction
7.2. Cardiovascular
7.3. Central Nervous System
7.4. Dermatology
7.5. Infectious Diseases
7.6. Metabolic And Endocrine
7.7. Oncology
7.7.1. Hematology
7.7.2. Solid Tumors
7.7.3. Supportive Care
7.8. Ophthalmology
7.9. Pain And Analgesia
7.10. Respiratory
8. Value-added Medicines Market, by Product Type
8.1. Introduction
8.2. Product Type
8.2.1. Drug Delivery Systems
8.2.1.1. Implantables
8.2.1.2. Inhalation Devices
8.2.1.3. Prefilled Syringes And Autoinjectors
8.2.1.4. Transdermal Systems
8.2.2. Fixed Dose Combination
8.2.3. Reformulations
8.2.3.1. Extended Release
8.2.3.2. Modified Release
8.2.3.3. Taste Masked And Pediatric Reformulations
8.2.4. Repositioning And New Indications
9. Value-added Medicines Market, by Technology
9.1. Introduction
9.2. Technology
9.2.1. Abuse Deterrent Formulations
9.2.2. Extended Release
9.2.3. Fixed Dose Combination Technology
9.2.4. Novel Excipient Platforms
9.2.5. Targeted Delivery And Nanocarriers
10. Value-added Medicines Market, by Dosage Form
10.1. Introduction
10.2. Inhalation
10.3. Injectable
10.4. Nasal
10.5. Ophthalmic
10.6. Oral Solid
10.7. Suppository
10.8. Topical
10.9. Transdermal Patch
11. Value-added Medicines Market, by Route Of Administration
11.1. Introduction
11.2. Inhalation
11.3. Nasal And Ocular
11.4. Oral
11.5. Parenteral
11.6. Topical
11.7. Transdermal
12. Value-added Medicines Market, by Indication Type
12.1. Introduction
12.2. Acute
12.3. Chronic
12.4. Palliative
12.5. Preventive
13. Value-added Medicines Market, by Age Group
13.1. Introduction
13.2. Adults
13.3. Geriatric
13.4. Neonatal
13.5. Pediatric
14. Value-added Medicines Market, by End User
14.1. Introduction
14.2. Home Healthcare
14.3. Hospital Pharmacy
14.4. Long Term Care
14.5. Online Pharmacy
14.6. Retail Pharmacy
14.7. Specialty Pharmacy
15. Value-added Medicines Market, by Distribution Channel
15.1. Introduction
15.2. Direct To Patient
15.3. Hospital Direct
15.4. Retail Channel
15.5. Specialty Distribution
15.6. Wholesale Distribution
16. Value-added Medicines Market, by Region
16.1. Introduction
16.2. Asia-Pacific
16.3. North America
16.4. Latin America
16.5. Europe
16.6. Middle East
16.7. Africa
17. Value-added Medicines Market, by Group
17.1. Introduction
17.2. ASEAN
17.3. GCC
17.4. European Union
17.5. BRICS
17.6. G7
17.7. NATO
18. Value-added Medicines Market, by Country
18.1. Introduction
18.2. United States
18.3. Canada
18.4. Mexico
18.5. Brazil
18.6. United Kingdom
18.7. Germany
18.8. France
18.9. Russia
18.10. Italy
18.11. Spain
18.12. China
18.13. India
18.14. Japan
18.15. Australia
18.16. South Korea
19. Competitive Landscape
19.1. Market Share Analysis, 2025
19.2. Market Concentration Analysis, 2025
19.2.1. Concentration Ratio (CR)
19.2.2. Herfindahl Hirschman Index (HHI)
19.3. Recent Developments & Impact Analysis, 2025
19.4. Product Portfolio Analysis, 2025
19.5. Benchmarking Analysis, 2025
20. Company Profiles
20.1. Abbott India Ltd
20.2. Ajanta Pharma Ltd
20.3. Akums Drugs & Pharmaceuticals Ltd
20.4. Alembic Pharmaceuticals Ltd
20.5. Alkem Laboratories Ltd
20.6. Aurobindo Pharma Ltd
20.7. Biocon Ltd
20.8. Cadila Pharmaceuticals Ltd
20.9. Cipla Ltd
20.10. Dr. Reddy's Laboratories Ltd
20.11. Eris Lifesciences Ltd
20.12. Gland Pharma Ltd
20.13. Glenmark Pharmaceuticals Ltd
20.14. Granules India Ltd
20.15. Gufic Biosciences Ltd
20.16. Indoco Remedies Ltd
20.17. Intas Pharmaceuticals Ltd
20.18. Jubilant Pharmova Ltd
20.19. Lupin Ltd
20.20. Mankind Pharma Ltd
20.21. NATCO Pharma Ltd
20.22. Neuland Laboratories Ltd
20.23. Piramal Pharma Ltd
20.24. Sun Pharmaceutical Industries Ltd
20.25. Torrent Pharmaceuticals Ltd
20.26. Unison Pharmaceuticals Private Limited
20.27. USV Private Limited
20.28. Windlas Biotech Limited
20.29. Wockhardt Ltd
20.30. Zydus Lifesciences Ltd
21. Key Experts
LIST OF FIGURES
FIGURE 1. Global Value-added Medicines Market, Years Considered for the Study
FIGURE 2. Global Value-added Medicines Market, Research Design
FIGURE 3. Global Value-added Medicines Market, Research Framework
FIGURE 4. Global Value-added Medicines Market, Data Triangulation
FIGURE 5. Global Value-added Medicines Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Value-added Medicines Market Size, by Therapeutic Area, 2025 vs 2032 (%)
FIGURE 7. Global Value-added Medicines Market Size, by Therapeutic Area, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Value-added Medicines Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 9. Global Value-added Medicines Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Value-added Medicines Market Size, by Technology, 2025 vs 2032 (%)
FIGURE 11. Global Value-added Medicines Market Size, by Technology, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Value-added Medicines Market Size, by Dosage Form, 2025 vs 2032 (%)
FIGURE 13. Global Value-added Medicines Market Size, by Dosage Form, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Value-added Medicines Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 15. Global Value-added Medicines Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Value-added Medicines Market Size, by Indication Type, 2025 vs 2032 (%)
FIGURE 17. Global Value-added Medicines Market Size, by Indication Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Value-added Medicines Market Size, by Age Group, 2025 vs 2032 (%)
FIGURE 19. Global Value-added Medicines Market Size, by Age Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Value-added Medicines Market Size, by End User, 2025 vs 2032 (%)
FIGURE 21. Global Value-added Medicines Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 22. Global Value-added Medicines Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 23. Global Value-added Medicines Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 24. Global Value-added Medicines Market Size, by Region, 2025 vs 2032 (%)
FIGURE 25. Global Value-added Medicines Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 26. Global Value-added Medicines Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 27. Global Value-added Medicines Market Size, by Country, 2025 vs 2032 (%)
FIGURE 28. Global Value-added Medicines Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 29. Global Value-added Medicines Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Value-added Medicines Market Segmentation & Coverage
TABLE 2. Global Value-added Medicines Market Size, 2017-2032 (USD Million)
TABLE 3. Global Value-added Medicines Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 4. Global Cardiovascular Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Cardiovascular Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Cardiovascular Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Central Nervous System Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Central Nervous System Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Central Nervous System Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Dermatology Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Dermatology Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Dermatology Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Infectious Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Infectious Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Infectious Diseases Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Metabolic And Endocrine Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Metabolic And Endocrine Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Metabolic And Endocrine Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Hematology Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Hematology Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Hematology Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Solid Tumors Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Solid Tumors Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Solid Tumors Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Supportive Care Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Supportive Care Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Supportive Care Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Ophthalmology Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Ophthalmology Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Ophthalmology Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Pain And Analgesia Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Pain And Analgesia Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Pain And Analgesia Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Respiratory Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Respiratory Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Respiratory Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Value-added Medicines Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 41. Global Product Type Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Product Type Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Product Type Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Drug Delivery Systems Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Drug Delivery Systems Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Drug Delivery Systems Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Implantables Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Implantables Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Implantables Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Inhalation Devices Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Inhalation Devices Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Inhalation Devices Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Prefilled Syringes And Autoinjectors Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Prefilled Syringes And Autoinjectors Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Prefilled Syringes And Autoinjectors Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Transdermal Systems Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Transdermal Systems Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Transdermal Systems Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Fixed Dose Combination Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Fixed Dose Combination Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Fixed Dose Combination Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global Reformulations Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global Reformulations Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global Reformulations Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global Extended Release Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Global Extended Release Market Size, by Group, 2017-2032 (USD Million)
TABLE 67. Global Extended Release Market Size, by Country, 2017-2032 (USD Million)
TABLE 68. Global Modified Release Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Global Modified Release Market Size, by Group, 2017-2032 (USD Million)
TABLE 70. Global Modified Release Market Size, by Country, 2017-2032 (USD Million)
TABLE 71. Global Taste Masked And Pediatric Reformulations Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Global Taste Masked And Pediatric Reformulations Market Size, by Group, 2017-2032 (USD Million)
TABLE 73. Global Taste Masked And Pediatric Reformulations Market Size, by Country, 2017-2032 (USD Million)
TABLE 74. Global Repositioning And New Indications Market Size, by Region, 2017-2032 (USD Million)
TABLE 75. Global Repositioning And New Indications Market Size, by Group, 2017-2032 (USD Million)
TABLE 76. Global Repositioning And New Indications Market Size, by Country, 2017-2032 (USD Million)
TABLE 77. Global Value-added Medicines Market Size, by Technology, 2017-2032 (USD Million)
TABLE 78. Global Technology Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Global Technology Market Size, by Group, 2017-2032 (USD Million)
TABLE 80. Global Technology Market Size, by Country, 2017-2032 (USD Million)
TABLE 81. Global Abuse Deterrent Formulations Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Global Abuse Deterrent Formulations Market Size, by Group, 2017-2032 (USD Million)
TABLE 83. Global Abuse Deterrent Formulations Market Size, by Country, 2017-2032 (USD Million)
TABLE 84. Global Extended Release Market Size, by Region, 2017-2032 (USD Million)
TABLE 85. Global Extended Release Market Size, by Group, 2017-2032 (USD Million)
TABLE 86. Global Extended Release Market Size, by Country, 2017-2032 (USD Million)
TABLE 87. Global Fixed Dose Combination Technology Market Size, by Region, 2017-2032 (USD Million)
TABLE 88. Global Fixed Dose Combination Technology Market Size, by Group, 2017-2032 (USD Million)
TABLE 89. Global Fixed Dose Combination Technology Market Size, by Country, 2017-2032 (USD Million)
TABLE 90. Global Novel Excipient Platforms Market Size, by Region, 2017-2032 (USD Million)
TABLE 91. Global Novel Excipient Platforms Market Size, by Group, 2017-2032 (USD Million)
TABLE 92. Global Novel Excipient Platforms Market Size, by Country, 2017-2032 (USD Million)
TABLE 93. Global Targeted Delivery And Nanocarriers Market Size, by Region, 2017-2032 (USD Million)
TABLE 94. Global Targeted Delivery And Nanocarriers Market Size, by Group, 2017-2032 (USD Million)
TABLE 95. Global Targeted Delivery And Nanocarriers Market Size, by Country, 2017-2032 (USD Million)
TABLE 96. Global Value-added Medicines Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 97. Global Inhalation Market Size, by Region, 2017-2032 (USD Million)
TABLE 98. Global Inhalation Market Size, by Group, 2017-2032 (USD Million)
TABLE 99. Global Inhalation Market Size, by Country, 2017-2032 (USD Million)
TABLE 100. Global Injectable Market Size, by Region, 2017-2032 (USD Million)
TABLE 101. Global Injectable Market Size, by Group, 2017-2032 (USD Million)
TABLE 102. Global Injectable Market Size, by Country, 2017-2032 (USD Million)
TABLE 103. Global Nasal Market Size, by Region, 2017-2032 (USD Million)
TABLE 104. Global Nasal Market Size, by Group, 2017-2032 (USD Million)
TABLE 105. Global Nasal Market Size, by Country, 2017-2032 (USD Million)
TABLE 106. Global Ophthalmic Market Size, by Region, 2017-2032 (USD Million)
TABLE 107. Global Ophthalmic Market Size, by Group, 2017-2032 (USD Million)
TABLE 108. Global Ophthalmic Market Size, by Country, 2017-2032 (USD Million)
TABLE 109. Global Oral Solid Market Size, by Region, 2017-2032 (USD Million)
TABLE 110. Global Oral Solid Market Size, by Group, 2017-2032 (USD Million)
TABLE 111. Global Oral Solid Market Size, by Country, 2017-2032 (USD Million)
TABLE 112. Global Suppository Market Size, by Region, 2017-2032 (USD Million)
TABLE 113. Global Suppository Market Size, by Group, 2017-2032 (USD Million)
TABLE 114. Global Suppository Market Size, by Country, 2017-2032 (USD Million)
TABLE 115. Global Topical Market Size, by Region, 2017-2032 (USD Million)
TABLE 116. Global Topical Market Size, by Group, 2017-2032 (USD Million)
TABLE 117. Global Topical Market Size, by Country, 2017-2032 (USD Million)
TABLE 118. Global Transdermal Patch Market Size, by Region, 2017-2032 (USD Million)
TABLE 119. Global Transdermal Patch Market Size, by Group, 2017-2032 (USD Million)
TABLE 120. Global Transdermal Patch Market Size, by Country, 2017-2032 (USD Million)
TABLE 121. Global Value-added Medicines Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 122. Global Inhalation Market Size, by Region, 2017-2032 (USD Million)
TABLE 123. Global Inhalation Market Size, by Group, 2017-2032 (USD Million)
TABLE 124. Global Inhalation Market Size, by Country, 2017-2032 (USD Million)
TABLE 125. Global Nasal And Ocular Market Size, by Region, 2017-2032 (USD Million)
TABLE 126. Global Nasal And Ocular Market Size, by Group, 2017-2032 (USD Million)
TABLE 127. Global Nasal And Ocular Market Size, by Country, 2017-2032 (USD Million)
TABLE 128. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 129. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 130. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 131. Global Parenteral Market Size, by Region, 2017-2032 (USD Million)
TABLE 132. Global Parenteral Market Size, by Group, 2017-2032 (USD Million)
TABLE 133. Global Parenteral Market Size, by Country, 2017-2032 (USD Million)
TABLE 134. Global Topical Market Size, by Region, 2017-2032 (USD Million)
TABLE 135. Global Topical Market Size, by Group, 2017-2032 (USD Million)
TABLE 136. Global Topical Market Size, by Country, 2017-2032 (USD Million)
TABLE 137. Global Transdermal Market Size, by Region, 2017-2032 (USD Million)
TABLE 138. Global Transdermal Market Size, by Group, 2017-2032 (USD Million)
TABLE 139. Global Transdermal Market Size, by Country, 2017-2032 (USD Million)
TABLE 140. Global Value-added Medicines Market Size, by Indication Type, 2017-2032 (USD Million)
TABLE 141. Global Acute Market Size, by Region, 2017-2032 (USD Million)
TABLE 142. Global Acute Market Size, by Group, 2017-2032 (USD Million)
TABLE 143. Global Acute Market Size, by Country, 2017-2032 (USD Million)
TABLE 144. Global Chronic Market Size, by Region, 2017-2032 (USD Million)
TABLE 145. Global Chronic Market Size, by Group, 2017-2032 (USD Million)
TABLE 146. Global Chronic Market Size, by Country, 2017-2032 (USD Million)
TABLE 147. Global Palliative Market Size, by Region, 2017-2032 (USD Million)
TABLE 148. Global Palliative Market Size, by Group, 2017-2032 (USD Million)
TABLE 149. Global Palliative Market Size, by Country, 2017-2032 (USD Million)
TABLE 150. Global Preventive Market Size, by Region, 2017-2032 (USD Million)
TABLE 151. Global Preventive Market Size, by Group, 2017-2032 (USD Million)
TABLE 152. Global Preventive Market Size, by Country, 2017-2032 (USD Million)
TABLE 153. Global Value-added Medicines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 154. Global Adults Market Size, by Region, 2017-2032 (USD Million)
TABLE 155. Global Adults Market Size, by Group, 2017-2032 (USD Million)
TABLE 156. Global Adults Market Size, by Country, 2017-2032 (USD Million)
TABLE 157. Global Geriatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 158. Global Geriatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 159. Global Geriatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 160. Global Neonatal Market Size, by Region, 2017-2032 (USD Million)
TABLE 161. Global Neonatal Market Size, by Group, 2017-2032 (USD Million)
TABLE 162. Global Neonatal Market Size, by Country, 2017-2032 (USD Million)
TABLE 163. Global Pediatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 164. Global Pediatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 165. Global Pediatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 166. Global Value-added Medicines Market Size, by End User, 2017-2032 (USD Million)
TABLE 167. Global Home Healthcare Market Size, by Region, 2017-2032 (USD Million)
TABLE 168. Global Home Healthcare Market Size, by Group, 2017-2032 (USD Million)
TABLE 169. Global Home Healthcare Market Size, by Country, 2017-2032 (USD Million)
TABLE 170. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 171. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 172. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 173. Global Long Term Care Market Size, by Region, 2017-2032 (USD Million)
TABLE 174. Global Long Term Care Market Size, by Group, 2017-2032 (USD Million)
TABLE 175. Global Long Term Care Market Size, by Country, 2017-2032 (USD Million)
TABLE 176. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 177. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 178. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 179. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 180. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 181. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 182. Global Specialty Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 183. Global Specialty Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 184. Global Specialty Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 185. Global Value-added Medicines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 186. Global Direct To Patient Market Size, by Region, 2017-2032 (USD Million)
TABLE 187. Global Direct To Patient Market Size, by Group, 2017-2032 (USD Million)
TABLE 188. Global Direct To Patient Market Size, by Country, 2017-2032 (USD Million)
TABLE 189. Global Hospital Direct Market Size, by Region, 2017-2032 (USD Million)
TABLE 190. Global Hospital Direct Market Size, by Group, 2017-2032 (USD Million)
TABLE 191. Global Hospital Direct Market Size, by Country, 2017-2032 (USD Million)
TABLE 192. Global Retail Channel Market Size, by Region, 2017-2032 (USD Million)
TABLE 193. Global Retail Channel Market Size, by Group, 2017-2032 (USD Million)
TABLE 194. Global Retail Channel Market Size, by Country, 2017-2032 (USD Million)
TABLE 195. Global Specialty Distribution Market Size, by Region, 2017-2032 (USD Million)
TABLE 196. Global Specialty Distribution Market Size, by Group, 2017-2032 (USD Million)
TABLE 197. Global Specialty Distribution Market Size, by Country, 2017-2032 (USD Million)
TABLE 198. Global Wholesale Distribution Market Size, by Region, 2017-2032 (USD Million)
TABLE 199. Global Wholesale Distribution Market Size, by Group, 2017-2032 (USD Million)
TABLE 200. Global Wholesale Distribution Market Size, by Country, 2017-2032 (USD Million)
TABLE 201. Global Value-added Medicines Market Size, by Region, 2017-2032 (USD Million)
TABLE 202. Asia-Pacific Value-added Medicines Market Size, by Region, 2017-2032 (USD Million)
TABLE 203. Asia-Pacific Value-added Medicines Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 204. Asia-Pacific Value-added Medicines Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 205. Asia-Pacific Value-added Medicines Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 206. Asia-Pacific Value-added Medicines Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 207. Asia-Pacific Value-added Medicines Market Size, by Drug Delivery Systems, 2017-2032 (USD Million)
TABLE 208. Asia-Pacific Value-added Medicines Market Size, by Reformulations, 2017-2032 (USD Million)
TABLE 209. Asia-Pacific Value-added Medicines Market Size, by Technology, 2017-2032 (USD Million)
TABLE 210. Asia-Pacific Value-added Medicines Market Size, by Technology, 2017-2032 (USD Million)
TABLE 211. Asia-Pacific Value-added Medicines Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 212. Asia-Pacific Value-added Medicines Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 213. Asia-Pacific Value-added Medicines Market Size, by Indication Type, 2017-2032 (USD Million)
TABLE 214. Asia-Pacific Value-added Medicines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 215. Asia-Pacific Value-added Medicines Market Size, by End User, 2017-2032 (USD Million)
TABLE 216. Asia-Pacific Value-added Medicines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 217. North America Value-added Medicines Market Size, by Region, 2017-2032 (USD Million)
TABLE 218. North America Value-added Medicines Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 219. North America Value-added Medicines Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 220. North America Value-added Medicines Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 221. North America Value-added Medicines Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 222. North America Value-added Medicines Market Size, by Drug Delivery Systems, 2017-2032 (USD Million)
TABLE 223. North America Value-added Medicines Market Size, by Reformulations, 2017-2032 (USD Million)
TABLE 224. North America Value-added Medicines Market Size, by Technology, 2017-2032 (USD Million)
TABLE 225. North America Value-added Medicines Market Size, by Technology, 2017-2032 (USD Million)
TABLE 226. North America Value-added Medicines Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 227. North America Value-added Medicines Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 228. North America Value-added Medicines Market Size, by Indication Type, 2017-2032 (USD Million)
TABLE 229. North America Value-added Medicines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 230. North America Value-added Medicines Market Size, by End User, 2017-2032 (USD Million)
TABLE 231. North America Value-added Medicines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 232. Latin America Value-added Medicines Market Size, by Region, 2017-2032 (USD Million)
TABLE 233. Latin America Value-added Medicines Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 234. Latin America Value-added Medicines Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 235. Latin America Value-added Medicines Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 236. Latin America Value-added Medicines Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 237. Latin America Value-added Medicines Market Size, by Drug Delivery Systems, 2017-2032 (USD Million)
TABLE 238. Latin America Value-added Medicines Market Size, by Reformulations, 2017-2032 (USD Million)
TABLE 239. Latin America Value-added Medicines Market Size, by Technology, 2017-2032 (USD Million)
TABLE 240. Latin America Value-added Medicines Market Size, by Technology, 2017-2032 (USD Million)
TABLE 241. Latin America Value-added Medicines Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 242. Latin America Value-added Medicines Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 243. Latin America Value-added Medicines Market Size, by Indication Type, 2017-2032 (USD Million)
TABLE 244. Latin America Value-added Medicines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 245. Latin America Value-added Medicines Market Size, by End User, 2017-2032 (USD Million)
TABLE 246. Latin America Value-added Medicines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 247. Europe Value-added Medicines Market Size, by Region, 2017-2032 (USD Million)
TABLE 248. Europe Value-added Medicines Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 249. Europe Value-added Medicines Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 250. Europe Value-added Medicines Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 251. Europe Value-added Medicines Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 252. Europe Value-added Medicines Market Size, by Drug Delivery Systems, 2017-2032 (USD Million)
TABLE 253. Europe Value-added Medicines Market Size, by Reformulations, 2017-2032 (USD Million)
TABLE 254. Europe Value-added Medicines Market Size, by Technology, 2017-2032 (USD Million)
TABLE 255. Europe Value-added Medicines Market Size, by Technology, 2017-2032 (USD Million)
TABLE 256. Europe Value-added Medicines Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 257. Europe Value-added Medicines Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 258. Europe Value-added Medicines Market Size, by Indication Type, 2017-2032 (USD Million)
TABLE 259. Europe Value-added Medicines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 260. Europe Value-added Medicines Market Size, by End User, 2017-2032 (USD Million)
TABLE 261. Europe Value-added Medicines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 262. Middle East Value-added Medicines Market Size, by Region, 2017-2032 (USD Million)
TABLE 263. Middle East Value-added Medicines Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 264. Middle East Value-added Medicines Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 265. Middle East Value-added Medicines Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 266. Middle East Value-added Medicines Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 267. Middle East Value-added Medicines Market Size, by Drug Delivery Systems, 2017-2032 (USD Million)
TABLE 268. Middle East Value-added Medicines Market Size, by Reformulations, 2017-2032 (USD Million)
TABLE 269. Middle East Value-added Medicines Market Size, by Technology, 2017-2032 (USD Million)
TABLE 270. Middle East Value-added Medicines Market Size, by Technology, 2017-2032 (USD Million)
TABLE 271. Middle East Value-added Medicines Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 272. Middle East Value-added Medicines Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 273. Middle East Value-added Medicines Market Size, by Indication Type, 2017-2032 (USD Million)
TABLE 274. Middle East Value-added Medicines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 275. Middle East Value-added Medicines Market Size, by End User, 2017-2032 (USD Million)
TABLE 276. Middle East Value-added Medicines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 277. Africa Value-added Medicines Market Size, by Region, 2017-2032 (USD Million)
TABLE 278. Africa Value-added Medicines Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 279. Africa Value-added Medicines Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 280. Africa Value-added Medicines Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 281. Africa Value-added Medicines Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 282. Africa Value-added Medicines Market Size, by Drug Delivery Systems, 2017-2032 (USD Million)
TABLE 283. Africa Value-added Medicines Market Size, by Reformulations, 2017-2032 (USD Million)
TABLE 284. Africa Value-added Medicines Market Size, by Technology, 2017-2032 (USD Million)
TABLE 285. Africa Value-added Medicines Market Size, by Technology, 2017-2032 (USD Million)
TABLE 286. Africa Value-added Medicines Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 287. Africa Value-added Medicines Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 288. Africa Value-added Medicines Market Size, by Indication Type, 2017-2032 (USD Million)
TABLE 289. Africa Value-added Medicines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 290. Africa Value-added Medicines Market Size, by End User, 2017-2032 (USD Million)
TABLE 291. Africa Value-added Medicines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 292. Global Value-added Medicines Market Size, by Group, 2017-2032 (USD Million)
TABLE 293. ASEAN Value-added Medicines Market Size, by Group, 2017-2032 (USD Million)
TABLE 294. ASEAN Value-added Medicines Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 295. ASEAN Value-added Medicines Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 296. ASEAN Value-added Medicines Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 297. ASEAN Value-added Medicines Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 298. ASEAN Value-added Medicines Market Size, by Drug Delivery Systems, 2017-2032 (USD Million)
TABLE 299. ASEAN Value-added Medicines Market Size, by Reformulations, 2017-2032 (USD Million)
TABLE 300. ASEAN Value-added Medicines Market Size, by Technology, 2017-2032 (USD Million)
TABLE 301. ASEAN Value-added Medicines Market Size, by Technology, 2017-2032 (USD Million)
TABLE 302. ASEAN Value-added Medicines Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 303. ASEAN Value-added Medicines Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 304. ASEAN Value-added Medicines Market Size, by Indication Type, 2017-2032 (USD Million)
TABLE 305. ASEAN Value-added Medicines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 306. ASEAN Value-added Medicines Market Size, by End User, 2017-2032 (USD Million)
TABLE 307. ASEAN Value-added Medicines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 308. GCC Value-added Medicines Market Size, by Group, 2017-2032 (USD Million)
TABLE 309. GCC Value-added Medicines Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 310. GCC Value-added Medicines Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 311. GCC Value-added Medicines Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 312. GCC Value-added Medicines Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 313. GCC Value-added Medicines Market Size, by Drug Delivery Systems, 2017-2032 (USD Million)
TABLE 314. GCC Value-added Medicines Market Size, by Reformulations, 2017-2032 (USD Million)
TABLE 315. GCC Value-added Medicines Market Size, by Technology, 2017-2032 (USD Million)
TABLE 316. GCC Value-added Medicines Market Size, by Technology, 2017-2032 (USD Million)
TABLE 317. GCC Value-added Medicines Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 318. GCC Value-added Medicines Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 319. GCC Value-added Medicines Market Size, by Indication Type, 2017-2032 (USD Million)
TABLE 320. GCC Value-added Medicines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 321. GCC Value-added Medicines Market Size, by End User, 2017-2032 (USD Million)
TABLE 322. GCC Value-added Medicines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 323. European Union Value-added Medicines Market Size, by Group, 2017-2032 (USD Million)
TABLE 324. European Union Value-added Medicines Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 325. European Union Value-added Medicines Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 326. European Union Value-added Medicines Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 327. European Union Value-added Medicines Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 328. European Union Value-added Medicines Market Size, by Drug Delivery Systems, 2017-2032 (USD Million)
TABLE 329. European Union Value-added Medicines Market Size, by Reformulations, 2017-2032 (USD Million)
TABLE 330. European Union Value-added Medicines Market Size, by Technology, 2017-2032 (USD Million)
TABLE 331. European Union Value-added Medicines Market Size, by Technology, 2017-2032 (USD Million)
TABLE 332. European Union Value-added Medicines Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 333. European Union Value-added Medicines Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 334. European Union Value-added Medicines Market Size, by Indication Type, 2017-2032 (USD Million)
TABLE 335. European Union Value-added Medicines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 336. European Union Value-added Medicines Market Size, by End User, 2017-2032 (USD Million)
TABLE 337. European Union Value-added Medicines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 338. BRICS Value-added Medicines Market Size, by Group, 2017-2032 (USD Million)
TABLE 339. BRICS Value-added Medicines Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 340. BRICS Value-added Medicines Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 341. BRICS Value-added Medicines Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 342. BRICS Value-added Medicines Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 343. BRICS Value-added Medicines Market Size, by Drug Delivery Systems, 2017-2032 (USD Million)
TABLE 344. BRICS Value-added Medicines Market Size, by Reformulations, 2017-2032 (USD Million)
TABLE 345. BRICS Value-added Medicines Market Size, by Technology, 2017-2032 (USD Million)
TABLE 346. BRICS Value-added Medicines Market Size, by Technology, 2017-2032 (USD Million)
TABLE 347. BRICS Value-added Medicines Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 348. BRICS Value-added Medicines Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 349. BRICS Value-added Medicines Market Size, by Indication Type, 2017-2032 (USD Million)
TABLE 350. BRICS Value-added Medicines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 351. BRICS Value-added Medicines Market Size, by End User, 2017-2032 (USD Million)
TABLE 352. BRICS Value-added Medicines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 353. G7 Value-added Medicines Market Size, by Group, 2017-2032 (USD Million)
TABLE 354. G7 Value-added Medicines Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 355. G7 Value-added Medicines Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 356. G7 Value-added Medicines Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 357. G7 Value-added Medicines Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 358. G7 Value-added Medicines Market Size, by Drug Delivery Systems, 2017-2032 (USD Million)
TABLE 359. G7 Value-added Medicines Market Size, by Reformulations, 2017-2032 (USD Million)
TABLE 360. G7 Value-added Medicines Market Size, by Technology, 2017-2032 (USD Million)
TABLE 361. G7 Value-added Medicines Market Size, by Technology, 2017-2032 (USD Million)
TABLE 362. G7 Value-added Medicines Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 363. G7 Value-added Medicines Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 364. G7 Value-added Medicines Market Size, by Indication Type, 2017-2032 (USD Million)
TABLE 365. G7 Value-added Medicines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 366. G7 Value-added Medicines Market Size, by End User, 2017-2032 (USD Million)
TABLE 367. G7 Value-added Medicines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 368. NATO Value-added Medicines Market Size, by Group, 2017-2032 (USD Million)
TABLE

Companies Mentioned

  • Abbott India Ltd
  • Ajanta Pharma Ltd
  • Akums Drugs & Pharmaceuticals Ltd
  • Alembic Pharmaceuticals Ltd
  • Alkem Laboratories Ltd
  • Aurobindo Pharma Ltd
  • Biocon Ltd
  • Cadila Pharmaceuticals Ltd
  • Cipla Ltd
  • Dr. Reddy's Laboratories Ltd
  • Eris Lifesciences Ltd
  • Gland Pharma Ltd
  • Glenmark Pharmaceuticals Ltd
  • Granules India Ltd
  • Gufic Biosciences Ltd
  • Indoco Remedies Ltd
  • Intas Pharmaceuticals Ltd
  • Jubilant Pharmova Ltd
  • Lupin Ltd
  • Mankind Pharma Ltd
  • NATCO Pharma Ltd
  • Neuland Laboratories Ltd
  • Piramal Pharma Ltd
  • Sun Pharmaceutical Industries Ltd
  • Torrent Pharmaceuticals Ltd
  • Unison Pharmaceuticals Private Limited
  • USV Private Limited
  • Windlas Biotech Limited
  • Wockhardt Ltd
  • Zydus Lifesciences Ltd

Related Reports

Value-added Medicines Development Service Market - Global Forecast 2026-2032 - Product Image

Value-added Medicines Development Service Market - Global Forecast 2026-2032

  • Report
  • 186 Pages
  • Global
From
Bio-Pharmaceutical Logistics Market - Global Forecast 2026-2032 - Product Image

Bio-Pharmaceutical Logistics Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Lutetium-177 Market - Global Forecast 2026-2032 - Product Image

Lutetium-177 Market - Global Forecast 2026-2032

  • Report
  • 193 Pages
  • Global
From
Alpha Emitters Market - Global Forecast 2026-2032 - Product Image

Alpha Emitters Market - Global Forecast 2026-2032

  • Report
  • 190 Pages
  • Global
From
Terbium-149 Market - Global Forecast 2026-2032 - Product Image

Terbium-149 Market - Global Forecast 2026-2032

  • Report
  • 190 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.